Navigation Links
Global Biotechnology Industry Market Research Report Now Available from IBISWorld
Date:4/16/2013

Los Angeles, CA (PRWEB) April 16, 2013

The Global Biotechnology industry comprises a large range of firms engaged in biotechnology activities. On one end are small, dedicated biotechnology companies that are research and development (R&D) intensive and operate primarily with venture capital, grants, initial public offerings and collaborative agreements. On the other end are large, diversified companies with significant in-house R&D resources and well-established production, commercialization and distribution processes. IBISWorld estimates that Global Biotechnology industry revenue will reach $262.0 billion in 2013, having increased at an average annual rate of 11.0% over the past five years. “Growth is expected to continue in 2013, with revenue expected to jump 12.7%,” says IBISWorld industry analyst Anna Son. This increase follows a relatively modest 8.7% rise in 2009, as the global recession eroded demand for nonessential health products and easing fuel prices tempered the biofuels craze. The greater effect the recession had on the industry, however, was that private investors became reluctant to provide capital because the collapse in stock prices prompted increased risk aversion. This investor reluctance eased in 2010, although investors remain highly sensitive to any economic weakness. Any prolonged lack of funding would reduce firms' R&D budgets, which, if not reversed, will jeopardize the industry's future revenue growth.

The Global Biotechnology industry continues to be populated by many small companies, alongside a few giant pharmaceutical, chemical and agricultural firms. IBISWorld estimates that the top industry players are Roche Holding AG, Amgen Inc. and Merck KGaA. Because companies specialize in certain diseases or products that are not transferable across other industry segments, concentration tends to stay low, says Son. In addition, the industry is still in the growth stage of its life cycle, and despite medium barriers to entry, new players are expected to enter the market to provide niche services. Furthermore, continuous technological advancements and the rapid growth of emerging markets leverage industry capabilities. Over the next five years, IBISWorld projects the industry will experience increased merger and acquisition activity as companies seek to expand their operations by acquiring domestic and foreign competitors. Nevertheless, market share concentration is not expected to increase substantially. Additionally, more biotechnology companies are partnering with pharmaceutical manufacturers as the pharmaceutical industry faces a patent cliff. In upcoming years, many blockbuster drugs will lose patent protection, exposing them to generic competition. This factor has increased the incentive for pharmaceutical firms to partner with biotechnology companies to develop biopharmaceutical drugs.

The vast majority of revenue is generated in the European Union and the United States, where the industry has shown growth over the past five years. The industry's major players reported recent slower growth rates for US sales compared with other parts of the world. This trend is expected to continue over the next five years as standards of living and healthcare access improve in emerging nations, such as India, China and Brazil. Over the next five years, the industry is expected to continue to prosper, with the Asia-Pacific region, particularly China, South Korea, Taiwan and Singapore, investing significant amounts of capital to gain a strong foothold in the industry. Larger players emerging as profitable entities following the global recession will continue pursuing low-risk strategies of success, including buying out smaller firms to collect successful research for commercial-ready technologies, and partnering with academic institutions. For more information, visit IBISWorld’s Global Biotechnology industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld
Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

Firms in this industry primarily use living organisms or molecular and cellular techniques to develop products that are used in agriculture, food, industrial and medicine production.

Industry Performance
Executive Summary
Key External Drivers
Current Performance
Industry Outlook
Industry Life Cycle
Products & Markets
Supply Chain
Products & Services
Major Markets
Globalization & Trade
Business Locations
Competitive Landscape
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Barriers to Entry
Major Companies
Operating Conditions
Capital Intensity
Key Statistics
Industry Data
Annual Change
Key Ratios

About IBISWorld Inc.
Recognized as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique industry information and analysis. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10636237.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Taylor-Wharton™ Announces Recent Appointments in its Global Operations
2. Neurovascular/Interventional Neurology Market [Aneurysm Coils, Carotid Stents, Microcatheter, Microguidewire, Liquid Embolic Agents, Cerebral Angioplasty Balloons] - Global Trends & Competitive Analysis - 2017
3. Pre-Clinical Imaging (In vivo) Market - by Systems and Reagents - Competitive Analysis & Global Forecasts to 2017
4. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
5. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
6. Global Virus Network Opens Headquarters in the University of Maryland BioPark
7. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
8. Lucintel Estimates Global High Density Polyethylene to Continue Growth over Next Five Years
9. Nerium International Receives the 2012 Global 100 Bravo Award for Growth
10. ISPE Releases New Guidance for Standardizing Use of Booklet Labels in Global Clinical Trials
11. Will Safety Concerns Slow Nanotechnology Drug Delivery Market Growth? Forecasts Predict 84.79% Growth in US, 73.97% Globally through 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Creative Medical ... Kesari , MD, PhD, FANA, FAAN to the Company,s ... neurology and clinical trials to assist the Company,s clinical ... stroke. The AmnioStem product is a universal donor stem cell ... activity in animal models of stroke 1 .  ...
(Date:12/6/2016)... 6, 2016  The Texas Medical Center ... (HISA) today announced the establishment of a new ... Australia and the Texas Medical ... HISA and the Texas Medical Center, with ... create a global health innovation ecosystem where emerging technologies ...
(Date:12/5/2016)... Axovant Sciences Ltd. (NYSE: AXON ... treatment of dementia, today announced that data on the ... disease will be presented at the 2016 Clinical Trials ... 2016 in San Diego . Intepirdine ... and complex measures of activities of daily living (ADLs) ...
(Date:12/5/2016)... ... December 05, 2016 , ... The Real Dirt with ... cannabis technology and application experts, Chip Baker. Chip Baker formerly co-founded Royal Gold ... past 30 years, Chip Baker other industry veterans have made the evolution of ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Avanade is ... Formula One teams in history, exploit biometric data in ... performance and maintain the competitive edge against their rivals ... Avanade has worked with Williams during ... of biometric data (heart rate, breathing rate, temperature and ...
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
Breaking Biology News(10 mins):